Search research articles
Contact Us
Filters
Showing results (771-780 of 788) with videos related to
Page
of 79
Sort By:
Lancet (London, England)
|
October 23, 2016
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
Jyh-Ming Liou, Yu-Jen Fang, Chieh-Chang Chen, et al.
Clinical and Molecular Hepatology
|
July 13, 2021
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Gut
|
January 7, 2021
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Hepatology International
|
March 7, 2021
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
Chen-Hua Liu, Po-Yueh Chen, Jyh-Jou Chen, et al.
Hepatology International
|
January 26, 2023
Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan
Chen-Hua Liu, Cheng-Yuan Peng, Chun-Jen Liu, et al.
Scientific Reports
|
December 7, 2021
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
Chung-Feng Huang, Hsing-Tao Kuo, Te-Sheng Chang, et al.
The Kaohsiung Journal of Medical Sciences
|
June 20, 2025
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in Taiwan
Szu-Jen Wang, Te-Sheng Chang, Ching-Chu Lo, et al.
Hepatology International
|
March 27, 2023
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry
Te-Sheng Chang, Chung-Feng Huang, Hsing-Tao Kuo, et al.
The Kaohsiung Journal of Medical Sciences
|
January 20, 2025
Real-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre-end-stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan
Szu-Jen Wang, Chung-Feng Huang, Te-Sheng Chang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
August 21, 2024
Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registry
Tyng-Yuan Jang, Chung-Feng Huang, Te-Sheng Chang, et al.
Page
of 79
Search research articles
Search
Showing results (771-780 of 788) with videos related to
Sort By:
Page
of 79
Lancet (London, England)
|
October 23, 2016
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
Jyh-Ming Liou, Yu-Jen Fang, Chieh-Chang Chen, et al.
Clinical and Molecular Hepatology
|
July 13, 2021
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Gut
|
January 7, 2021
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Hepatology International
|
March 7, 2021
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
Chen-Hua Liu, Po-Yueh Chen, Jyh-Jou Chen, et al.
Hepatology International
|
January 26, 2023
Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan
Chen-Hua Liu, Cheng-Yuan Peng, Chun-Jen Liu, et al.
Scientific Reports
|
December 7, 2021
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
Chung-Feng Huang, Hsing-Tao Kuo, Te-Sheng Chang, et al.
The Kaohsiung Journal of Medical Sciences
|
June 20, 2025
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in Taiwan
Szu-Jen Wang, Te-Sheng Chang, Ching-Chu Lo, et al.
Hepatology International
|
March 27, 2023
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry
Te-Sheng Chang, Chung-Feng Huang, Hsing-Tao Kuo, et al.
The Kaohsiung Journal of Medical Sciences
|
January 20, 2025
Real-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre-end-stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan
Szu-Jen Wang, Chung-Feng Huang, Te-Sheng Chang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
August 21, 2024
Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registry
Tyng-Yuan Jang, Chung-Feng Huang, Te-Sheng Chang, et al.
Page
of 79